Breast Cancer: Value-Based Healthcare, Costs and Financing
DOI:
https://doi.org/10.20344/amp.9093Keywords:
Breast Neoplasms/economics, Cost-Benefit Analysis, Costs and Cost Analysis, Health Care CostAbstract
Introduction: Breast cancer is the second most common oncological disease worldwide. To analyse the new disease specific funding programme (breast cancer) implemented at the Francisco Gentil Portuguese Institute of Oncology, Lisbon Center (Instituto Português de Oncologia de Lisboa Francisco Gentil), the actual costs of the patients were examined using activity-based costing as a costing methodology. This study addresses the following question: “How much does it cost to treat breast cancer per ‘patient-month’ compared to the monthly fixed ‘funding envelope’?”.
Materials and Methods: The study cohort consisted of 807 patients, corresponding to all the patients eligible for the new disease specific funding programme and who were enrolled during the first year of implementation. Activity-based costing was used to calculate the total real costs per stage of disease and per ‘patient-month’ as well as the deviation from the monthly fixed ‘funding envelope’.
Results: The total costs were 6.6 M€, whereas the total funding was 5.2 M€ for a total of 5648 ‘patient-months’. In 2014, the balance difference between the funding obtained and the actual costs was -1.4 €M for the cohort of 807 patients.
Discussion: The extreme cases of differences in cost per ‘patient-month’ compared to the monthly fixed ‘funding envelope’ were (i) stage 0/Tis, with higher funding at 415.23 € per ‘patient-month’, and (ii) stage IIIC, with lower funding at 1062.79 € per ‘patient-month’.
Conclusion: The ‘patient-month’ cost, regardless of disease stage was 1170.29 €. The median deviation per ‘patient-month’ was negative (241.21 €) compared to the monthly fixed ‘funding envelope’ of 929.08 € in the first year. Establishing activity-based costing - funding models will be crucial for the future sustainability of the healthcare sector.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.